Kevin Auton
Kevin Auton
Aseptika Limited (Activ8rlives)

Kevin Auton, Ph.D., is the Managing Director and Founder of Aseptika Limited (Activ8rlives). Kevin has developed self-monitoring using connected devices and services under the Activ8rlives brand, launching a range of consumer-facing, ‘cross-over’ medical devices in the UK, sales of which are increasing year-on-year. Kevin is passionate about healthcare and supporting others to learn how to self-manage their long-term conditions after developing a process for his own family.

In 2000, Kevin founded NextGen Sciences which was listed on AiM in 2005 at a valuation of £20 million,and Cellexus Biosystems which was listed on Plus Markets but had to go into administration at the start of the financial crash when investment suddenly dried-up, despite achieving all goals and milestones and initiated sales in the USA, UK, EU and Australia.

Learning from this experience, Kevin has built Aseptika with the support of the team drawn to the company’s ethos, in a slow, boot-strapped business model, generating early revenues, building an outward-facing and customer-focused attitude and de-risking technology development with grants and early revenues –and not adopting a biotech-burn model of the company’s comparators/competitors.

Kevin is the inventor of 9 granted patents, including ‘Biomarkers for Respiratory Disease’ now granted around the world and ‘Respiratory Exercise Tolerance Index –BuddyWOTCH’ both of which he has assigned to the company. Kevin spends a lot of his time writing grant applications, loves running the Active+ classes teaching self-care using Activ8rlives and gets a buzz from leading commercialisation activities to exploit the company’s technologies and converting this into products.

My Sessions
Bringing to Market: Asthma+me
-
Presentation HealthTech Stage D80

 


4,000
ATTENDEES
150
EXHIBITORS
3
CONFERENCE STAGES
34
COUNTRIES REPRESENTED

Thanks to our supporters